Evidence map›Paper›PMID 33419057›Full record

ArticleJournal of personalized medicine2021

miR-210 and miR-152 as Biomarkers by Liquid Biopsy in Invasive Ductal Carcinoma.

Beatriz C Lopes, Cristine Z Braga, Fabrício V Ventura, Jéssica G de Oliveira, Edson M Kato-Junior, Newton A Bordin-Junior, Debora A P C Zuccari

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of personalized medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Hypoxia-driven ncRNAs in breast cancer.Frontiers in oncology · 2023
    Review
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Beatriz C LopesInstitute of Biosciences, Letters and Exact Sciences (IBILCE), Sao Jose do Rio Preto, Sao Paulo 15054-000, Brazil.
Cristine Z BragaFaculdade de Medicina de Sao Jose do Rio Preto (FAMERP), Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil.
Fabrício V VenturaFaculdade de Medicina de Sao Jose do Rio Preto (FAMERP), Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil.
Jéssica G de OliveiraFaculdade de Medicina de Sao Jose do Rio Preto (FAMERP), Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil.
Edson M Kato-JuniorFaculdade de Medicina de Sao Jose do Rio Preto (FAMERP), Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil.
Newton A Bordin-JuniorHospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Sao Paulo 15090-000, Brazil.
Debora A P C ZuccariInstitute of Biosciences, Letters and Exact Sciences (IBILCE), Sao Jose do Rio Preto, Sao Paulo 15054-000, Brazil.
Faculdade de Medicina de São José do Rio Preto · BRHospital de Base · BR

Funding

Fundação de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) 2017/11807-3Fundação de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) 2017/15006-5Fundação de Apoio à Pesquisa e Extensão de Sao Jose do Rio Preto (FAPERP) 028/2018
6 · The paper itself

Abstract

Detecting circulating microRNAs (miRNAs; miRs) by means of liquid biopsy is an important tool for the early diagnosis and prognosis of breast cancer (BC). We aimed to identify and validate miR-210 and miR-152 as non-invasive circulating biomarkers, for the diagnosis and staging of BC patients, confirming their involvement in tumor angiogenesis.

methodsRT-qPCR was performed and MiRNA expression analysis was obtained from plasma and fragments of BC and benign breast condition (BBC) women patients, plus healthy subjects. Additionally, the immunohistochemistry technique was carried out to analyze the expression of target proteins.

resultsTumor fragments showed increased expression of oncomiR-210 and decreased expression of miR-152 tumoral suppressor. Both miRNAs were increased in plasma samples from BC patients. The receiver operating characteristic (ROC) curve analysis revealed that only the expression of oncomiR-210 in tissue samples and only the expression of the miR-152 suppressor in plasma have the appropriate sensitivity and specificity for use as differential biomarkers between early/intermediate and advanced stages of BC patients. In addition, there was an increase in the expression of hypoxia-inducible factor 1-alpha (HIF-1α), insulin-like growth factor 1 receptor (IGF-1R), and vascular endothelial growth factor (VEGF) in BC patients. On the contrary, a decrease in Von Hippel-Lindau (VHL) protein expression was observed.

conclusionsThis study showed that increased levels of miR-210 and decreased levels of miR152, in addition to the expressions of their target proteins, could indicate, respectively, the oncogenic and tumor suppressive role of these miRNAs in fragments. Both miRNAs are potential diagnostic biomarkers for BC by liquid biopsy. In addition, miR-152 proved to be a promising biomarker for disease staging.

Indexed as

angiogenesisbiomarkersbreast cancerearly diagnosisliquid biopsymiRNAs

Identifiers

PMID33419057
PMCPMC7825421
OpenAlexW3119445215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.